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significance level of 0.05 was used for these analyses. RESULTS: Overall 7,261 en-
rolleeswere included in the analysis. Out of these, 187 (2.6%) hadHF at baseline and
1,075 (14.8%) experienced HF for the first time. Mean LOS was 4.29 (7.5) days but
increased significantly to 8.8 (17.6) days in case of new onset HF (  5.20.2,
p0.001) and to 9.7 (10.5) days if pre-existing HF was included as a major comor-
bidity (  6.00.7, p0.001) during index hospitalization. Hospitalization costs
(log-transformed) were associated with recording of new onset HF (  0.40.02,
p0.001) but not with reporting of pre-existing HF (  0.10.1, p0.1451) as a
comorbid condition during index hospitalization.CONCLUSIONS:Newonset of HF,
recorded as a major comorbid condition, in STEMI patients undergoing PCI exhib-
ited significant independent association with resource utilization including in-
creased length of stay and greater costs.
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OBJECTIVES: To evaluate persistence and compliance of fixed dose combinations
in comparison to unfixed dose combinations of angiotensin receptor blockers
(ARBs) in patients with hypertension in Germany. METHODS: This retrospective
study analyzed prescription data collected by general practitioners, using a longi-
tudinal database, the German IMS Disease Analyzer (DA). The DA database was
searched for patients with hypertension (ICD-10 code I10) who were initiated on
double or triple combinations of ARBs with hydrochlorothiazide (HCT) and/or am-
lodipine (AML) in the period 09/2008-08/2009with a follow-up of at least 12months.
Persistence was defined as proportion of patients who remained on their initially
prescribed therapy at 1 year. The difference between mean persistence values
(days) were calculated by using multiple regression analyses adjusted by age, gen-
der, region, insurance and co-morbidity. Compliance was measured indirectly
based on the medication possession ratio calculated as number of days supplied
within the refill interval in relation to the number of days in the refill interval.
RESULTS:Overall, 17,310 patientswere eligible for analysis: 35.7% on a fixed double
ARB combination, 33.0% on an unfixed double ARB combination, 25.9% on a semi-
fixed triple ARB combination, and 5.4% on an unfixed triple ARB combination.
Twelve months after first prescription persistence on unfixed versus semi-fixed
ARB/HCTAML triple combination was 32.7% and 46.7 % respectively, unfixed ver-
sus semi-fixed ARB/AMLHCT triple combination was 41.5% and 49.0% respec-
tively, unfixed versus fixed ARB/HCT double combination 23,8% and 41.1% respec-
tively, unfixed versus fixed ARB/AML double combination 27.5% and 44.4%
respectively. Mean days of persistence was higher in patients receiving fixed com-
binations (225.7-242.9) compared to unfixed combinations (163.6-228.0). Mean
compliance value with fixed combinations ranged between 72.0%-79.0%, with un-
fixed combinations between 71.5-76.2%. CONCLUSIONS: These real-life data con-
firms previous study results, that fixed combinations improve persistence in pa-
tients compared to unfixed combinations because of reduced pill burden.
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OBJECTIVES: Compare statin adherence, persistence, and health care costs among
patients in whom atorvastatin (AS), simvastatin (SS), rosuvastatin (RS), or prava-
statin (PS) was newly prescribed.METHODS: Study patients 18 years were iden-
tified betweenOctober 1, 2006-September 30, 2007, with aminimum12-month pre-
and 24-month post-index health plan eligibility from a managed care database. A
6-month washout period free of any statin use was applied to identify patients in
whom statin therapywas newly prescribed. The index datewas defined as the date
of the first statin prescription and four cohortswere created based on index statins:
AS, SS, RS, and PS. These cohorts were matched according to propensity scores
based on patient clinical and demographic characteristics. Outcomes were com-
pared among matched cohorts during the 2-year post-index period, including ad-
herence to any statin (medication possession ratio0.8), time to any statin discon-
tinuation, and health care costs. RESULTS: After matching, 6185 patients were
obtained in each cohort and the baseline characteristics were balanced among
cohorts. Half of the patients were adherent to their statin therapy at 12 months
(52.2% for SS, 47.3% for AS, 48.6% for RS, and 49.7% for PS, P0.01), with further
decline at 24 months (43.1% for SS, 38.0% for AS, 39.2% for RS, and 38.5% for PS,
P0.01). Median time to any statin discontinuation within 24 months were less
than 1 year for all cohorts (SS: 308 days; AS: 250 days; RS: 266 days; PS: 301 days,
P0.01). The cohorts had slightly different 2-year health care costs (SS: $15,417; AS:
$16,826; RS: $15,874; PS: $15,481, P0.01) with the most difference attributable to
the lower drug costs (SS: $4460; AS: $5485; RS: $5424; PS: $4586, P0.01).
CONCLUSIONS: Patients had low adherence and persistence rates to statin ther-
apy. Patients initiating different statins had varying adherence and persistence
profiles, including 2-year health care costs.
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OBJECTIVES: The objective was to determine the impact of Medicare part D dough-
nut hole or the ‘coverage gap’ on medication compliance behavior and healthcare
resource utilization among Medicare beneficiaries taking statin medications.
METHODS: This was a retrospective cohort study using a 2007 5% National sample
of Medicare beneficiaries. Beneficiaries enrolled in the Part D programwith at least
1 prescription claim for statin were included in the study. Patients were classified
as continuers, switchers and discontinuers of statinmedications after reaching the
coverage gap. The primary outcomes of interest were average number of emer-
gency room (ER) visits, hospitalizations, out of pocket (OoP) costs and number of
prescriptions pre and post coverage gap. RESULTS: 131237 patients met the inclu-
sion criteria. All patients in the study sample were diagnosedwith hyperlipidemia,
and 8,251 patients were prescribedwith statins as a primary prevention treatment.
Of the beneficiaries taking statins, 65.8% were female; 80.71% white; 10.91% black
and themean age was 71.9 (12.0) years. Overall, 24.3% of statin users reached the
coverage gap in 2007, with 10.2% reaching the gap by March, 42.0% by June, and
74.4% by September. Within 90 days after reaching the gap, 74.2% of statin users
continued using their statin medication, 1.0% switched to a different statin medi-
cation, and 24.8% discontinued use of statins. After reaching the coverage gap, the
average number of ER visits/month increased from 0.24 to 0.25 and the average OoP
costs/month increased from $58.51 to $104.03. CONCLUSIONS: The results suggest
an overall negative impact of the Medicare part D coverage gap on enrollee health,
adherence to statin medications, number of hospitalizations, emergency depart-
ment visits and out of pocket expenses incurred by beneficiaries. The disruption of
the coverage gap on the quality of care is demonstrated by the large percentage of
statin users discontinuing therapy.
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OBJECTIVES:To evaluate treatment compliance and persistence in patients receiv-
ing fixed combinations compared to patients receiving unfixed combinations with
olmesartan medoxomil for hypertension treatment in Germany. METHODS: This
retrospective study analyzed prescription data collected by general practitioners,
using a longitudinal database, the German IMS Disease Analyzer (DA). The DA
database was searched for patients with hypertension (ICD-10 code I10) who were
initiated on double or triple combinations of olmesartan medoxomil with hydro-
chlorothiazide and/or amlodipine in the period 09/2008-08/2009with a follow-up of
at least 12 months. Persistence was defined as proportion of patients who re-
mained on their initially prescribed therapy at 1 year. The difference between
mean persistence values (days) were calculated by using multiple regression anal-
yses adjusted by age, gender, region, insurance and co-morbidity. Compliance was
measured indirectly based on the medication possession ratio calculated as num-
ber of days suppliedwithin the refill interval in relation to thenumber of days in the
refill interval. RESULTS: In total, 7,360 patients were eligible for analysis, 58.0%
were treated with a fixed or semi-fixed combination of olmesartan and 42.0% with
a dual or triple unfixed combination of olmesartan. After 12 months following the
first prescription, fixed or semi-fixed combinations had a higher rate of persistence
(43.4%-50.2%) compared to dual or triple unfixed combinations (25.0%-35.8%).Mean
duration of persistence was higher in patients receiving dual or triple fixed or
semi-fixed combinations (222.5-242.7 days) compared to patients receiving unfixed
combinations (183.6-205.0 days). Mean compliance value with olmesartan in all
combinations ranged between 70.0% 80.0%. CONCLUSIONS: Overall, persistence
is increased in patients receiving fixed combinations of olmesartan in comparison
to free combinations. These real-life data confirms previous study results, that
persistence of fixed combinations in comparison to unfixed combinations is im-
proved because of reduced pill burden.
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OBJECTIVES: The impact of health behaviors (e.g., medication adherence) on out-
comes (e.g., hospitalizations) has been widely explored in literature, but few stud-
ies have evaluated the reverse association. We investigated the impact of cardio-
vascular disease (CVD) hospitalizations on changes in adherence to
antihypertensive (AH) drugs.METHODS:Maryland Medicaid claims data from Jan-
uary 2001 to June 2006 were analyzed. The index date for patients with a CVD
hospitalization was the admission date of the first observed CVD-related hospital-
ization. Matched controls had the same index date as index patients. Proportion of
days covered (PDC) was used to measure medication adherence (adherence:
PDC80%). Patients with and without a CVD hospitalization were matched 1:1, on
the first pharmacy claim (6month) of any AH drugs recorded in the database, age
(5 years), gender, race, number of drugs taken in the 6-month pre-index period
(1 drug), and adherence rate to AH drugs in the 6-month pre-index period (5%
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